title: Rose hip herbal remedy in patients with rheumatoid arthritis - a randomised controlled trial.
abstract: OBJECTIVE
  To investigate if standardised powder made from rose-hip (Rosa canina) can reduce the symptom score in patients with rheumatoid arthritis.
  
  
  METHODS
  In a double-blind placebo-controlled trial, patients with rheumatoid arthritis (RA) according to ARA/ACR criteria were randomised to treatment with capsulated rose-hip powder 5g daily or matching placebo for 6 months at two outpatient clinics in Berlin and Copenhagen. Primary outcome variable was Health Assessment Questionnaire (HAQ) at 6 months, secondary outcome included DAS-28, physician's global evaluation of disease activity, RAQoL, SF-12 and concomitant pain medication.
  
  
  RESULTS
  In a total of 89 patients (90% female, mean age 56.6+11.3 years, mean disease duration 12.8+9.6 years) HAQ-DI in the rose-hip group improved by 0.105+/-0.346, whereas in the placebo group it worsened by 0.039+/-0.253 (p adjusted=0.032). In the HAQ Patient Pain Scale no significant differences were observed between both groups. In the HAQ Patient Global Scale a trend was seen favouring rose-hip (p=0.078). The DAS-28 score yielded improvement in the rose-hip group of 0.89+/-1.32 and in the placebo group of 0.34+/-1.27 (p=0.056) indicating moderate clinical relevance. The Physicians Global Scale demonstrated more improvement in the rose-hip compared to the placebo group (p=0.012). RAQoL and SF-12 physical score improved significantly in the rose-hip group compared to placebo, whereas SF-12 mental score remained unchanged. Intake of pain medication was not different between the groups. Per-protocol analysis confirmed these results.
  
  
  CONCLUSIONS
  The results indicate that patients with RA may benefit from additional treatment with rose hip powder.
authors.affiliation: Institute for Social Medicine, Epidemiology and Health Economics, Charité University Medical Centre, Berlin, Germany.
authors.forename: S N
authors.initials: SN
authors.lastname: Willich
authors.forename: K
authors.initials: K
authors.lastname: Rossnagel
authors.forename: S
authors.initials: S
authors.lastname: Roll
authors.forename: A
authors.initials: A
authors.lastname: Wagner
authors.forename: O
authors.initials: O
authors.lastname: Mune
authors.forename: J
authors.initials: J
authors.lastname: Erlendson
authors.forename: A
authors.initials: A
authors.lastname: Kharazmi
authors.forename: H
authors.initials: H
authors.lastname: Sörensen
authors.forename: K
authors.initials: K
authors.lastname: Winther
mesh_terms: D000368:Aged; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005638:Fruit; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D008517:Phytotherapy; D028321:Plant Preparations / Q000627:therapeutic use*; D011208:Powders; D027826:Rosa
chemical_list: D028321:Plant Preparations; D011208:Powders